Financial Contrast: Zura Bio (NASDAQ:ZURA) vs. Caribou Biosciences (NASDAQ:CRBU)

Zura Bio (NASDAQ:ZURA) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current recommendations and price targets for Zura Bio and Caribou Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1	1	3	1	2.67
Caribou Biosciences	1	0	2	1	2.75

Zura Bio presently has a consensus target price of $10.75, suggesting a potential upside of 190.54%. Caribou Biosciences has a consensus target price of $8.67, suggesting a potential upside of 443.36%. Given Caribou Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Zura Bio.

Volatility & Risk

Zura Bio has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500.

Earnings and Valuation

This table compares Zura Bio and Caribou Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35 million	($1.09)	-3.39
Caribou Biosciences	$11.16 million	14.17	-$148.12 million	($1.42)	-1.12

Zura Bio has higher earnings, but lower revenue than Caribou Biosciences. Zura Bio is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zura Bio and Caribou Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Insider & Institutional Ownership

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Zura Bio beats Caribou Biosciences on 7 of the 13 factors compared between the two stocks.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.